JNT-517 Tablet

DRUG4 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

PhenylketonuriaPhenylketonuria (PKU)

Phase 1

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Active, not recruitingNCT05781399

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria

Start: 2022-10-31End: 2025-12-15Target: 135Updated: 2025-07-31

Phase 2

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

RecruitingNCT06637514

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria (PKU)

Start: 2025-07-16End: 2026-02-28Target: 10Updated: 2025-08-19

Phase 3

A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria

Not yet recruitingNCT06628128

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria (PKU)

Start: 2025-06-30End: 2028-02-29Target: 45Updated: 2025-06-03

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

RecruitingNCT06971731

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria

Start: 2025-10-20End: 2028-04-01Target: 120Updated: 2026-04-02